TL;DR
This randomized controlled study investigated whether partially covered duodenal stents (PCDS) offer an advantage over uncovered duodenal stents (UCDS) for unresectable malignant gastric outlet obstruction (GOO). While PCDS showed a trend towards reduced tumor ingrowth, neither stent type significantly improved reintervention rates or stent patency, suggesting both are viable options for this patient group.
What Problem Does This Paper Address?
Malignant gastric outlet obstruction (GOO) is a serious complication of advanced cancers, often leading to severe symptoms like nausea, vomiting, and inability to eat. Endoscopic stenting is a common palliative treatment to restore patency. Traditionally, uncovered duodenal stents (UCDS) have been used, but they are prone to tumor ingrowth, which can cause restenosis and require reintervention. Fully covered stents have been explored to mitigate ingrowth but carry a higher risk of migration. Partially covered duodenal stents (PCDS) were developed to balance these issues, with a covered portion to reduce ingrowth and an uncovered portion to improve stent fixation and minimize migration. However, robust evidence comparing PCDS and UCDS in a well-powered study was lacking, prompting this investigation into their comparative efficacy.
Methods
This was a prospective, international, multicenter randomized controlled study involving 10 high-volume institutions. Consecutive patients diagnosed with unresectable primary malignant GOO were recruited. Patients were randomly assigned to receive either a partially covered duodenal stent (PCDS) or an uncovered duodenal stent (UCDS). The primary outcome measured was the reintervention rate, defined as the percentage of patients requiring additional endoscopic intervention due to stent dysfunction. Secondary outcomes included technical and clinical success, 30-day adverse events, 30-day mortality, causes of stent dysfunction, and stent patency duration. Procedures were performed by experienced endoscopists using a standard endoscopic approach with guidewire and stent deployment under fluoroscopic guidance. For PCDS, the uncovered portion was intentionally placed proximal to the tumor to facilitate coverage by the covered portion.
Datasets
Not discussed in the paper. The study involved patient recruitment and data collection from 10 participating institutions.
Key Insights and Ideas
- The "Best of Both Worlds" Hypothesis Tested: The study directly tested the hypothesis that PCDS, by combining covered and uncovered sections, would offer superior outcomes (reduced ingrowth and migration) compared to UCDS.
- Tumor Ingrowth Remains a Challenge: Despite the covered portion of PCDS, tumor ingrowth was still observed, albeit with a trend towards being less frequent than with UCDS. This highlights that even partially covered stents are not entirely immune to this complication.
- Reintervention Rates are Similar: The core finding is the lack of significant difference in reintervention rates between the two stent types. This suggests that the theoretical benefits of PCDS in preventing ingrowth did not translate into a clinically meaningful reduction in the need for repeat procedures in this study population.
- Anchoring vs. Ingrowth Trade-off: The uncovered portion of the PCDS likely aids in stent fixation, as evidenced by the absence of stent migration in the PCDS arm. However, this same portion can still be a site for tumor ingrowth, illustrating the inherent trade-off in stent design.
Key Results
- A total of 115 patients were recruited (59 in the PCDS group and 56 in the UCDS group).
- The 1-year reintervention rate was not significantly different between the groups: 20.3% for PCDS versus 25% for UCDS (P = 0.84).
- There was a trend towards fewer patients experiencing tumor ingrowth in the PCDS group (10.2%) compared to the UCDS group (23.2%), but this did not reach statistical significance (P = 0.07).
- No significant differences were observed in technical success (100% for both), clinical success (91.5% vs. 98.2%), procedural time, hospital stay, 30-day adverse events, or 30-day mortality.
- Stent migration was not observed in the PCDS group, suggesting the uncovered portion provided adequate anchorage.
Limitations and Future Work
- Trend vs. Significance: The observed trend of reduced tumor ingrowth with PCDS did not reach statistical significance, possibly due to sample size limitations or the nature of the disease.
- Extrinsic Tumors Excluded: The study specifically excluded patients with extrinsic tumor compression, which might be a group where stent migration is a more significant concern and where PCDS might show different results.
- Other Causes of Reintervention: While tumor ingrowth was a focus, other causes of reintervention (e.g., gastroparesis, inadequate expansion) were observed, indicating that stent type alone may not be the sole determinant of long-term patency.
- Future Directions: The authors suggest that alternative endoscopic treatments, such as EUS-guided gastrojejunostomy, might offer a more promising approach by placing the stent further from the tumor, potentially reducing reintervention needs. They also note that advances in chemotherapy could influence tumor response and stent outcomes.
Summary updated